• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cognition Therapeutics, Inc. - Common Stock (NQ:CGTX)

    1.115 -0.035 (-3.04%)
    Streaming Delayed Price Updated: 11:39 AM EDT, Jul 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 863,902
    Open 1.180
    Bid (Size) 1.120 (1,200)
    Ask (Size) 1.130 (1,000)
    Prev. Close 1.150
    Today's Range 1.110 - 1.220
    52wk Range 0.2933 - 3.830
    Shares Outstanding 88,268,078
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Keep an eye on the top gainers and losers in Wednesday's session. ↗
    Via Chartmill
    Here are the top movers in Wednesday's session. ↗
    Via Chartmill

    Performance

    YTD
    -24.1%
    -24.1%
    1 Month
    -10.8%
    -10.8%
    3 Month
    +46.8%
    +46.8%
    6 Month
    -18.6%
    -18.6%
    1 Year
    +259.9%
    +259.9%

    More News

    Read More
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    News headline image
    Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    Cognition Therapeutics (NASDAQ:CGTX) Narrows Loss, Eyes Key FDA Meeting on DLB Drug ↗
    Via Chartmill
    News headline image
    Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics CEO Issues Letter to Shareholders
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
    From Cognition Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Here are the top movers in Monday's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Cognition Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Cognition Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Cognition Therapeutics, Inc. - Common Stock trade on?
    Cognition Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Cognition Therapeutics, Inc. - Common Stock?
    The ticker symbol for Cognition Therapeutics, Inc. - Common Stock is CGTX on the Nasdaq Stock Market
    What is the current price of Cognition Therapeutics, Inc. - Common Stock?
    The current price of Cognition Therapeutics, Inc. - Common Stock is 1.115
    When was Cognition Therapeutics, Inc. - Common Stock last traded?
    The last trade of Cognition Therapeutics, Inc. - Common Stock was at 07/01/26 11:39 AM ET
    What is the market capitalization of Cognition Therapeutics, Inc. - Common Stock?
    The market capitalization of Cognition Therapeutics, Inc. - Common Stock is 98.42M
    How many shares of Cognition Therapeutics, Inc. - Common Stock are outstanding?
    Cognition Therapeutics, Inc. - Common Stock has 98M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.